CN114746102A - 用于治疗性处理代谢综合征的姜黄素类组合物 - Google Patents

用于治疗性处理代谢综合征的姜黄素类组合物 Download PDF

Info

Publication number
CN114746102A
CN114746102A CN202080081641.8A CN202080081641A CN114746102A CN 114746102 A CN114746102 A CN 114746102A CN 202080081641 A CN202080081641 A CN 202080081641A CN 114746102 A CN114746102 A CN 114746102A
Authority
CN
China
Prior art keywords
demethoxycurcumin
mammal
hexahydrocurcuminoids
octahydrocurcuminoids
tetrahydrocurcuminoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080081641.8A
Other languages
English (en)
Chinese (zh)
Inventor
M.马吉德
K.纳加布沙南
L.蒙德克尔
R.拉马努贾姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Sabinsha Group Co ltd
Original Assignee
Sami Sabinsha Group Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Sabinsha Group Co ltd filed Critical Sami Sabinsha Group Co ltd
Publication of CN114746102A publication Critical patent/CN114746102A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080081641.8A 2019-10-15 2020-10-15 用于治疗性处理代谢综合征的姜黄素类组合物 Pending CN114746102A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962915068P 2019-10-15 2019-10-15
US62/915,068 2019-10-15
PCT/US2020/055796 WO2021076766A1 (en) 2019-10-15 2020-10-15 Curcuminoid composition for therapeutic management of metabolic syndrome

Publications (1)

Publication Number Publication Date
CN114746102A true CN114746102A (zh) 2022-07-12

Family

ID=75382361

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080081641.8A Pending CN114746102A (zh) 2019-10-15 2020-10-15 用于治疗性处理代谢综合征的姜黄素类组合物
CN202080079524.8A Pending CN114728876A (zh) 2019-10-15 2020-10-15 姜黄素类组合物及其处理肺纤维化的治疗潜力

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080079524.8A Pending CN114728876A (zh) 2019-10-15 2020-10-15 姜黄素类组合物及其处理肺纤维化的治疗潜力

Country Status (6)

Country Link
US (2) US11707438B2 (https=)
EP (2) EP4045478B1 (https=)
JP (2) JP2022553173A (https=)
CN (2) CN114746102A (https=)
CA (2) CA3153877C (https=)
WO (2) WO2021076766A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230255969A1 (en) * 2020-07-23 2023-08-17 National University Of Singapore Targeting immune pathologies induced by highly pathogenic coronaviruses
JP2023554640A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド 慢性炎症状態において終末糖化産物受容体（ｒａｇｅ）を標的とするための組成物
WO2022203674A1 (en) * 2021-03-25 2022-09-29 Majeed, Muhammed Compositions and methods for managing nephropathy
BR112023022756A2 (pt) * 2021-04-30 2024-01-02 Sami Sabinsa Group Ltd Composições para gerenciamento de síndrome de ovário policístico

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646473A (zh) * 2002-04-17 2005-07-27 北卡罗来纳查佩尔山大学 新的姜黄素类似物和其用途
CN102526004A (zh) * 2010-01-25 2012-07-04 四川省中医药科学院 四氢姜黄素的新用途
US20170258743A1 (en) * 2014-12-15 2017-09-14 Aurea Biolabs Private Limited A Process for Preparation of Bioavailable White Curcumin - A Unique Blend of Hydrogenated Curcuminoids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0249747A (ja) 1988-08-12 1990-02-20 Kobe Steel Ltd 抗酸化剤
US6653327B2 (en) * 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
JP2003002827A (ja) * 2001-06-20 2003-01-08 Kyowa Hakko Kogyo Co Ltd 血中中性脂肪の増加の予防又は改善剤
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20060263309A1 (en) * 2005-05-17 2006-11-23 Bissett Donald L Regulation of mammalian keratinous tissue using personal care compositions comprising tetrahydrocurcumin
US20080031980A1 (en) * 2006-08-02 2008-02-07 Al Rodriguez Curcumin-containing composition, methods of making, and methods of using
US20080058426A1 (en) * 2006-08-29 2008-03-06 Muhammed Majeed Composition and method for treating psoriasis
CN101255119B (zh) * 2008-01-07 2014-05-21 沈阳药科大学 四氢姜黄素衍生物及盐类
JP2012521412A (ja) * 2009-03-23 2012-09-13 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． 鼻のアレルギー疾患において適用するためのクルクミノイドおよびその代謝物
CN101732292B (zh) * 2010-01-25 2012-05-16 四川省中医药科学院 四氢姜黄素的用途
WO2011124573A1 (en) * 2010-04-09 2011-10-13 Unilever Plc Oral care compositions
CN102078312A (zh) * 2010-12-24 2011-06-01 中国药科大学 一种姜黄素类化合物干粉吸入剂及其制备方法和用途
US9170257B2 (en) * 2012-06-14 2015-10-27 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
US20150283093A1 (en) * 2014-04-07 2015-10-08 Muhammed Majeed Nanoencapsulation of curcuminoid metabolites - process, composition and applications thereof
US9642886B2 (en) * 2014-08-25 2017-05-09 Srm University Plant based formulation for the prevention and management of metabolic syndrome by its adiponectin enhancing property
KR102876481B1 (ko) * 2017-03-17 2025-10-27 케랄라 아유르베다 리미티드 (인디아) 약초 조성물
CN108771664B (zh) * 2018-06-05 2020-09-08 中山大学 四氢姜黄素在改善过敏性哮喘的应用
CN109833457A (zh) * 2019-02-28 2019-06-04 孟凤仙 虎杖及姜黄及其活性物在治疗间质性肺病中的应用
CN109674742A (zh) * 2019-03-07 2019-04-26 康赋葆(深圳)生物医药科技有限公司 一种姜黄素类亲水凝胶骨架缓释组合物、制备方法及其在抗癌领域的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646473A (zh) * 2002-04-17 2005-07-27 北卡罗来纳查佩尔山大学 新的姜黄素类似物和其用途
CN102526004A (zh) * 2010-01-25 2012-07-04 四川省中医药科学院 四氢姜黄素的新用途
US20170258743A1 (en) * 2014-12-15 2017-09-14 Aurea Biolabs Private Limited A Process for Preparation of Bioavailable White Curcumin - A Unique Blend of Hydrogenated Curcuminoids

Also Published As

Publication number Publication date
EP4045478B1 (en) 2026-01-28
US11491119B2 (en) 2022-11-08
CA3153877C (en) 2024-04-02
US20210106544A1 (en) 2021-04-15
EP4045071A1 (en) 2022-08-24
EP4045478A4 (en) 2024-01-10
CA3153879A1 (en) 2021-04-22
CA3153877A1 (en) 2021-04-22
EP4045071A4 (en) 2023-11-29
CN114728876A (zh) 2022-07-08
EP4045071B1 (en) 2026-02-25
EP4045478A1 (en) 2022-08-24
WO2021076766A1 (en) 2021-04-22
WO2021076771A1 (en) 2021-04-22
US20210106543A1 (en) 2021-04-15
JP2022551967A (ja) 2022-12-14
US11707438B2 (en) 2023-07-25
JP2022553173A (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
Ulla et al. Supplementation of Syzygium cumini seed powder prevented obesity, glucose intolerance, hyperlipidemia and oxidative stress in high carbohydrate high fat diet induced obese rats
EP4045071B1 (en) Curcuminoid composition for therapeutic management of metabolic syndrome
Prabhakar et al. Synergistic interaction of ferulic acid with commercial hypoglycemic drugs in streptozotocin induced diabetic rats
Rajasekaran et al. Beneficial effects of aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetes.
Yoshikawa et al. Salacia reticulata and its polyphenolic constituents with lipase inhibitory and lipolytic activities have mild antiobesity effects in rats
Tsai et al. Antioxidant effects of diallyl trisulfide on high glucose-induced apoptosis are mediated by the PI3K/Akt-dependent activation of Nrf2 in cardiomyocytes
Cho et al. Alternation of hepatic antioxidant enzyme activities and lipid profile in streptozotocin-induced diabetic rats by supplementation of dandelion water extract
Abdel-Wahab Protective effect of thymoquinone on sodium fluoride-induced hepatotoxicity and oxidative stress in rats
Park et al. Cyanidin and malvidin in aqueous extracts of black carrots fermented with Aspergillus oryzae prevent the impairment of energy, lipid and glucose metabolism in estrogen-deficient rats by AMPK activation
James et al. Dietary pretreatment with green tea polyphenol,(−)-epigallocatechin-3-gallate reduces the bioavailability and hepatotoxicity of subsequent oral bolus doses of (−)-epigallocatechin-3-gallate
Park et al. Preventive effects of a purified extract isolated from Salvia miltiorrhiza enriched with tanshinone I, tanshinone IIA and cryptotanshinone on hepatocyte injury in vitro and in vivo
Jan et al. Evaluation of antidiabetic potential of steroidal alkaloid of Sarcococca saligna
Al-Numair Hypocholesteremic and antioxidant effects of garlic (Allium sativum L.) extract in rats fed high cholesterol diet
CN107949394A (zh) 包含黑豆叶提取物及从其分离的黄酮醇苷作为活性成分的用于预防或治疗代谢综合征或用于抗氧化的组合物
Peng et al. GC‐(4→ 8)‐GCG, A Proanthocyanidin Dimer from Camellia ptilophylla, Modulates Obesity and Adipose Tissue Inflammation in High‐Fat Diet Induced Obese Mice
US9011936B2 (en) Extract of Rosmarinus officinalis L. leaves for pharmaceutical applications
CA2847543C (en) Annatto extract compositions, including geranyl geraniols and methods of use
Mokiran et al. Effect of dabai (Canarium odontophyllum) fruit extract on biochemical parameters of induced obese–diabetic rats
Oh et al. Low molecular weight blue mussel hydrolysates inhibit adipogenesis in mouse mesenchymal stem cells through upregulating HO-1/Nrf2 pathway
Geetha et al. Anti diabetic effect of Achyranthes rubrofusca leaf extracts on alloxan induced diabetic rats
Budiman et al. Potency of turmeric (Curcuma longa L.) extract and curcumin as anti-obesity by inhibiting the cholesterol and triglycerides synthesis in HepG2 cells
Jako et al. Passiflora edulis extract ameliorates HFD-induced hepatic steatosis mediated through Nrf2 and IRS-1 activation, NFκB suppression, and hepatic lipid metabolism and bile acid modulation in obese rats
Uthirapathy Cardioprotection effects of diosgenin from Dioscorea bulbifera against isoproterenol-induced myocardial infarction
Nithiya et al. Protective effect of phloretin on hyperglycemia mediated oxidative stress in experimental diabetic rats
Ebrahimi et al. Effects of hydroalcoholic flower extract of marigold (Calendula officinalis) on the biochemical and histological parameters in STZ-induced diabetic rats

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220712